New agents for bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancer

Current Opinion in Urology

Volumn 24, Issue 5, 2014, Pages 540-545

  Ahn, Jennifer J ^a   Ghandour, Rashed A ^a   McKiernan, James M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

bacillus Calmette Gu rin refractory; intravesical therapy; nonmuscle invasive bladder cancer; salvage agents

Indexed keywords

BCG VACCINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EXOTOXIN; GEMCITABINE; HYALURONIC ACID; IMMUNOTOXIN; MITOMYCIN; OPORTUZUMAB MONATOX; PACLITAXEL; TAXANE DERIVATIVE; VALRUBICIN;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CYSTECTOMY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HYPERTHERMIC THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; CARCINOMA, TRANSITIONAL CELL; DRUG THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; MORTALITY; MYCOBACTERIUM BOVIS; PROCEDURES; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM BOVIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84905401644     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000088     Document Type: Review

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Babjuk M, Oosterlinck W, Sylvester R, et al. [EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder, the 2011 update]. Actas Urol Esp 2012; 36:389-402.
3. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314-2330.
4. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
5. Rubben H, Lutzeyer W, Fischer N, et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988; 139:283-285.
6. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, nonmuscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011; 60:493-500.
7. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169:1706-1708.
8. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66(6 Suppl 1) :108-125.
9. Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161:1124-1127.
10. Mishina T, Watanabe H, Kobayashi T, et al. Absorption of anticancer drugs through bladder epithelium. Urology 1986; 27:148-157.
11. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther 2008; 8:1809-1818.
12. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: a systematic review. Eur Urol 2011; 60:81-93.
13. Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Longterm outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for nonmuscleinvasive bladder cancer (NMIBC). BJU Int 2011; 107:912-918.
14. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009; 182:1313-1317.
15. Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 2011; 29:259-264.
16. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46:65-71.
17. Zargar H, Aning J, Ischia J, et al. Optimizing intravesical mitomycin C therapy in nonmuscle-invasive bladder cancer. Nature reviews. Urology 2014; 11:220-230.
18. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170:777-782.
19. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7:43-51.
20. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial nonmuscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011; 12:871-879.
21. Sockett LJ, Borwell J, Symes A, et al. Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk noninvasive bladder cancer and failure of BCG immunotherapy. BJU Int 2008; 101 (Suppl 5):50.
22. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20:3193-3198.
23. Lorusso V, Carpagnano F, Frasci G, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of nonsmall-cell lung cancer. J Clin Oncol 2000; 18:405-411.
24. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005; 66:726-731.
25. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24:2729-2734.
26. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. J Urol 2013; 190:1200-1204.
27. Grossman HB, O'Donnell MA, Cookson MS, et al. Bacillus calmette-guerin failures and beyond: contemporary management of nonmuscle-invasive bladder cancer. Rev Urol 2008; 10:281-289.
28. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163:761-767.
29. Calabro F, Sternberg CN. Localized and locally advanced bladder cancer. Curr Treat Options Oncol 2002; 3:413-428.
30. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006; 24:3075-3080.
31. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of nonmuscleinvasive bladder cancer refractory to standard intravesical therapy. Urology 2010; 75:134-137.
32. Barlow L, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol 2013; 189:834-839.
33. Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19:899-909.
34. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005; 11:4136-4143.
35. McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol 2011; 186:448-451.
36. Bassi PF, Volpe A, D'Agostino D, et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol 2011; 185:445-449.
37. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific singlechain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003; 9:2837-2848.
38. Kowalski M, Entwistle J, Cizeau J, et al. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Develop Ther 2010; 4:313-320.
39. Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol 2012; 188:1712-1718.
40. Lee JY, Diaz RR, Cho KS, et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy. J Urol 2013; 190:1192-1199.
41. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001; 166:1633-1637.
42. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol 2009; 181:1040-1045.
43. Lightfoot AJ, Breyer BN, Rosevear HM, et al. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for nonmuscle invasive bladder cancer. Urol Oncol 2014; 32:e15-e39.
44. Chen CH, Yang HJ, Shun CT, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for nonmuscle-invasive bladder cancer. Urol Oncol 2012; 30:421-427.
45. Jarow JP, Lerner SP, Kluetz PG, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology 2014; 83:262-264.